Literature DB >> 16686258

Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus.

H I Brunner1, A Bishnoi, A C Barron, L J Houk, A Ware, Y Farhey, A B Mongey, C F Strife, T B Graham, M H Passo.   

Abstract

The objective of this study was to determine the medical outcomes including the ovarian function childhood-onset SLE (cSLE). The medical records of all patients diagnosed with cSLE in the Greater Cincinnati area between 1981 and 2002 were reviewed. Patient interviews were performed to obtain additional information on current medication regimens, disease activity [SLE Disease Activity Index (SLEDAI-2k)], and damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)]. The occurence of premature ovarian failure (POF) and reduction of the ovarian reserve was assessed by timed gonadotropin levels. There were 77 patients (F : M = 70 : 7, 53% Caucasian, 45% African-American and 2% Asian) with a mean age at diagnosis of 14.6 years. Nine patients died (88.3% survival) during the mean follow-up of 7.1 years (standard deviation [SD] 5.6) and 88% of the patients continued to have active disease (SLEDAI-2k mean/SD: 6.6/6.7), with 42% of them having disease damage (SDI mean/SD: 1.62/2.1); Non-Caucasian patients had higher disease activity (mean SLEDAI-2k: 10 versus 3.4; P < 0.0001) and more disease damage (mean SDI : 2.1 versus 1.2; P < 0.02) than Caucasian patients. Cyclophosphamide was given to 47% of the patients during the course of their disease and associated with the presence of significantly reduced ovarian reserve (RR = 2.8; 95% CI: 1.7-4.8; P = 0.026). Patient mortality and disease damage with cSLE continue to be high. Although overt POF with cyclophosphamide exposure is rare, it is a risk factor for significantly decreased ovarian reserve cSLE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686258     DOI: 10.1191/0961203306lu2291oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

1.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study.

Authors:  Artemis Koutsonikoli; Maria Trachana; Anna-Bettina Heidich; Vasiliki Galanopoulou; Polyxeni Pratsidou-Gertsi; Alexandros Garyphallos
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

Review 3.  Adult outcomes of childhood-onset rheumatic diseases.

Authors:  Aimee Hersh; Emily von Scheven; Ed Yelin
Journal:  Nat Rev Rheumatol       Date:  2011-04-12       Impact factor: 20.543

4.  Nonmalignant diseases and treatments associated with primary ovarian failure: an expanded role for fertility preservation.

Authors:  Jennifer Hirshfeld-Cytron; Clarisa Gracia; Teresa K Woodruff
Journal:  J Womens Health (Larchmt)       Date:  2011-08-09       Impact factor: 2.681

5.  The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus.

Authors:  Ronald T Brown; Stephanie R Shaftman; Barbara C Tilley; Kelly K Anthony; Mary C Kral; Bonnie Maxson; Laura Mee; Melanie J Bonner; Larry B Vogler; Laura E Schanberg; Mark A Connelly; Janelle L Wagner; Richard M Silver; Paul J Nietert
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

Review 6.  Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding.

Authors:  Nicole Bitencourt; Bonnie L Bermas
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

7.  Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Patricia Vega-Fernandez; Shana Vanderburgh White; Frank Zelko; Natasha M Ruth; Deborah M Levy; Eyal Muscal; Marisa S Klein-Gitelman; Adam M Huber; Lori B Tucker; Tresa Roebuck-Spencer; Jun Ying; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-08       Impact factor: 4.794

8.  Examining Uncertainty in Illness in Parents and Children With Chronic Kidney Disease and Systemic Lupus Erythematosus: A Mediational Model of Internalizing Symptoms and Health-Related Quality of Life.

Authors:  Jennifer L Petrongolo; Nataliya Zelikovsky; Rachel M Keegan; Susan L Furth; Andrea Knight
Journal:  J Clin Psychol Med Settings       Date:  2020-03

9.  17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice.

Authors:  K A Shelton; J M Cline; J A Cann
Journal:  Atherosclerosis       Date:  2013-01-18       Impact factor: 5.162

10.  Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.

Authors:  Aimee O Hersh; Emily von Scheven; Jinoos Yazdany; Pantelis Panopalis; Laura Trupin; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Rheum       Date:  2009-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.